News

Asarina Pharma shows efficacy of Sepranolone in Tourette’s syndrome on par with current first line treatment, but without side effects

Stockholm, April 2, 2019: Sepranolone reduces tics in an animal model of Tourette’s syndrome on par with Haldol, without inducing any motor side effects.

Full PDF

Asarina Pharma Year-End Report 2018 shows solid progress

Stockholm, 25 February, 2019: Asarina Pharma AB releases its Year-End Report including financials for the fourth quarter 2018 and for the full year 2018. (READ THE FULL YEAR-END REPORT IN PDF HERE (http://docs.wixstatic.com/ugd/641552_cd037716c08b48c69d458724079a39d2.pdf).)

Full PDF

Asarina Pharma Scientific Advisory Board gives full backing to Menstrual Migraine Phase IIA trial

Stockholm – December 18, 2018. On December 17 Asarina Pharma’s Scientific Advisory Board (SAB) gave its full backing to the company’s upcoming trial of a new preventive treatment for Menstrual Migraine. The SAB comprises world-leading independent scientists in obstetrics, gynaecology, neurology and pharmacology, including Prof Anne MacGregor, one of the world’s foremost authorities on headache…

Full PDF

Asarina Pharma CSO presents at PMS event in Stockholm: ‘It’s time to talk about PMDD’

Torbjörn Bäckström, Asarina Pharma CSO, and Karin Ekberg, COO, spoke at PMS & PMDD Day on November 21, at Medelhavsmuseet, Stockholm. A wide range of PMS researchers, educators and activists took part. “It’s fantastic to see this billed as PMS and PMDD Day,” says Asarina Pharma CEO Peter Nordkild. “It shows how much knowledge of…

Full PDF

Interim Report July-September 2018

Clinical trials on track Stockholm, 14 November, 2018: Asarina Pharma AB releases its Interim Report for 1 July – 30 September, 2018.

Full PDF